Rapt Therapeutics (RAPT) Expected to Announce Earnings on Thursday

Rapt Therapeutics (NASDAQ:RAPT) is expected to release its Q4 2025 results before the market opens on Thursday, March 5th. Analysts expect Rapt Therapeutics to post earnings of ($0.92) per share for the quarter. Parties can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Friday, March 13, 2026 at 10:30 AM ET.

Rapt Therapeutics Trading Up 0.1%

Rapt Therapeutics stock opened at $58.02 on Wednesday. Rapt Therapeutics has a 52 week low of $5.67 and a 52 week high of $58.02. The stock has a market cap of $1.61 billion, a price-to-earnings ratio of -5.25 and a beta of 0.49. The company’s 50-day moving average price is $48.60 and its two-hundred day moving average price is $33.68.

Wall Street Analyst Weigh In

Several research firms have weighed in on RAPT. Wells Fargo & Company cut shares of Rapt Therapeutics from an “overweight” rating to an “equal weight” rating and set a $58.00 price objective on the stock. in a research report on Tuesday, January 20th. JPMorgan Chase & Co. increased their price target on shares of Rapt Therapeutics from $55.00 to $57.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 12th. Piper Sandler downgraded Rapt Therapeutics from an “overweight” rating to a “neutral” rating and set a $58.00 price objective on the stock. in a research note on Tuesday, January 20th. Barclays downgraded shares of Rapt Therapeutics from an “overweight” rating to an “equal weight” rating and set a $58.00 target price on the stock. in a report on Wednesday, January 21st. Finally, HC Wainwright lowered Rapt Therapeutics from a “buy” rating to a “neutral” rating and set a $58.00 price target for the company. in a report on Tuesday, January 20th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Rapt Therapeutics presently has a consensus rating of “Hold” and an average target price of $48.44.

Institutional Investors Weigh In On Rapt Therapeutics

A number of hedge funds have recently made changes to their positions in the company. Invesco Ltd. increased its stake in shares of Rapt Therapeutics by 411.7% in the first quarter. Invesco Ltd. now owns 58,901 shares of the company’s stock valued at $72,000 after buying an additional 47,391 shares in the last quarter. AQR Capital Management LLC acquired a new stake in Rapt Therapeutics in the 1st quarter valued at about $188,000. Bank of Nova Scotia acquired a new stake in Rapt Therapeutics in the 4th quarter valued at about $227,000. Dimensional Fund Advisors LP bought a new position in shares of Rapt Therapeutics in the third quarter worth about $231,000. Finally, Voloridge Investment Management LLC acquired a new position in shares of Rapt Therapeutics during the fourth quarter worth approximately $233,000. Institutional investors and hedge funds own 99.09% of the company’s stock.

About Rapt Therapeutics

RAPT Therapeutics, Inc (NASDAQ:RAPT) is a clinical-stage biotechnology company developing novel therapeutics for autoimmune and allergic diseases. Founded in 2013 and headquartered in San Diego, California, RAPT applies tissue-selective immunology to design small molecule and biologic candidates that modulate immune cell trafficking and tissue-resident pathways. The company’s research platform enables the identification of targets that drive tissue inflammation with the goal of achieving improved efficacy and safety profiles over current therapies.

The company’s lead asset, RPT193, is an orally available antagonist of the CC chemokine receptor 4 (CCR4), currently in clinical development for atopic dermatitis and allergic asthma.